OOIR: Observatory of International Research

Papers

(The TQCC of Journal of Neurodevelopmental Disorders is 13. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-04-01 to 2024-04-01.)

Article	Citations
Early life stress and development: potential mechanisms for adverse outcomes	142
Controlling litter effects to enhance rigor and reproducibility with rodent models of neurodevelopmental disorders	52
Developmental studies in fragile X syndrome	45
Controlled trial of lovastatin combined with an open-label treatment of a parent-implemented language intervention in youth with fragile X syndrome	43
Comparison of SHANK3 deficiency in animal models: phenotypes, treatment strategies, and translational implications	40
Behavioral features in Prader-Willi syndrome (PWS): consensus paper from the International PWS Clinical Trial Consortium	35
Behavioural and psychological features of PTEN mutations: a systematic review of the literature and meta-analysis of the prevalence of autism spectrum disorder characteristics	31
Behavioural and neural markers of tactile sensory processing in infants at elevated likelihood of autism spectrum disorder and/or attention deficit hyperactivity disorder	31
Translational outcomes relevant to neurodevelopmental disorders following early life exposure of rats to chlorpyrifos	29
Pre-symptomatic intervention for autism spectrum disorder (ASD): defining a research agenda	28
The prevalence and profile of autism in individuals born preterm: a systematic review and meta-analysis	26
Obsessive-compulsive disorder and attention-deficit/hyperactivity disorder: distinct associations with DNA methylation and genetic variation	26
FOXP1 syndrome: a review of the literature and practice parameters for medical assessment and monitoring	23
Resting state EEG in youth with ASD: age, sex, and relation to phenotype	22
Current neurologic treatment and emerging therapies in CDKL5 deficiency disorder	22
Maternal immune response and air pollution exposure during pregnancy: insights from the Early Markers for Autism (EMA) study	22
Evidence of neuroinflammation and immunotherapy responsiveness in individuals with down syndrome regression disorder	21
Risk of neurodevelopmental disorders in children born from different ART treatments: a systematic review and meta-analysis	21
Feasibility of delivering parent-implemented NDBI interventions in low-resource regions: a pilot randomized controlled study	21
Utilization of telemedicine to support caregivers of young children with ASD and their Part C service providers: a comparison of intervention outcomes across three models of service delivery	20
Characterisation of the clinical phenotype in Phelan-McDermid syndrome	20
Telehealth-enabled behavioral treatment for problem behaviors in boys with fragile X syndrome: a randomized controlled trial	19
A small-molecule screen reveals novel modulators of MeCP2 and X-chromosome inactivation maintenance	18
Functional characterization of rare NRXN1 variants identified in autism spectrum disorders and schizophrenia	18
Capturing cognitive and behavioral variability among individuals with Down syndrome: a latent profile analysis	17

Neurodevelopmental and psychiatric disorders in females with Turner syndrome: a population-based study	17
Spoken language outcome measures for treatment studies in Down syndrome: feasibility, practice effects, test-retest reliability, and construct validity of variables generated from expressive language	17
Prediction of autism spectrum disorder diagnosis using nonlinear measures of language-related EEG at 6 and 12 months	17
mTOR inhibitor improves autistic-like behaviors related to Tsc2 haploinsufficiency but not following developmental status epilepticus	17
A randomized, controlled trial of ZYN002 cannabidiol transdermal gel in children and adolescents with fragile X syndrome (CONNECT-FX)	16
A randomized, double-blind, placebo-controlled phase II trial to explore the effects of a GABAA-α5 NAM (basmisanil) on intellectual disability associated with Down syndrome	15
Anxiety-like behavior and anxiolytic treatment in the Rett syndrome natural history study	15
Associations between sensory processing and electrophysiological and neurochemical measures in children with ASD: an EEG-MRS study	15
Early differences in auditory processing relate to Autism Spectrum Disorder traits in infants with Neurofibromatosis Type I	15
Intellectual abilities, language comprehension, speech, and motor function in children with spinal muscular atrophy type 1	14
Affective and psychotic reactivity to daily-life stress in adults with 22q11DS: a study using the experience sampling method	14
Natural clusters of tuberous sclerosis complex (TSC)-associated neuropsychiatric disorders (TAND): new findings from the TOSCA TAND research project	14
Transcriptome analysis of neural progenitor cells derived from Lowe syndrome induced pluripotent stem cells: identification of candidate genes for the neurodevelopmental and eye manifestations	13
Conducting clinical trials in persons with Down syndrome: summary from the NIH INCLUDE Down syndrome clinical trials readiness working group	13
Evidence for decreased parasympathetic response to a novel peer interaction in older children with autism spectrum disorder: a case-control study	13
The electroretinogram b-wave amplitude: a differential physiological measure for Attention Deficit Hyperactivity Disorder and Autism Spectrum Disorder	13
The diagnostic journey of genetically defined neurodevelopmental disorders	13
Trajectories of imitation skills in preschoolers with autism spectrum disorders	13
Social cognition in 22q11.2 deletion syndrome and idiopathic developmental neuropsychiatric disorders	13
Reflections on the genetics-first approach to advancements in molecular genetic and neurobiological research on neurodevelopmental disorders	13